Skip to main content
In this week's special podcast, Dr. Jack Cush offers a primer on rheumatology clinical trials, answering the question: should you be involved in research and clinical trials in rheumatology?
ACR Announces 2022 Award Recipients

The ACR and the ARP proudly recognizes the recipients of its 2022 Master of the AC

Dr. John Cush RheumNow

3 years 11 months ago
ACR Announces 2022 Award Recipients The ACR and the ARP proudly recognizes the recipients of its 2022 Master of the ACR and ARP designations, ACR Awards of Distinction, and ARP Awards of Merit and Appreciation. https://t.co/sB3IfvFBJD https://t.co/w8J4qFPvpF
Do you renal Bx your #SLE pts? Study of 277 SLE pts w/ US-guided percutaneous renal bx showed bleeding complications pos

Dr. John Cush RheumNow

3 years 11 months ago
Do you renal Bx your #SLE pts? Study of 277 SLE pts w/ US-guided percutaneous renal bx showed bleeding complications post biopsy to be 19.9% (minor 13%; major 7%); risk higher w/ thrombocytopenia (OR 7.12)low eGFR (OR 3.5) https://t.co/kYieyYTUuT https://t.co/ZGobCIcW6v
EMA CHMP issued a positive opinion on the safety of Filgotinib, a selective JAK1 inhibitor, based on testicular safety d

Dr. John Cush RheumNow

3 years 11 months ago
EMA CHMP issued a positive opinion on the safety of Filgotinib, a selective JAK1 inhibitor, based on testicular safety data from the MANTA & MANTA-RAy studies. Gilead withdrew filgotinib from US market w/ FDA concerns on testicular safety in 12/20 https://t.co/EawqOGZEZe https://t.co/Bcp6rOReCR
A study from the Georgia Lupus Registry shows that systemic lupus erythematosus patients are at greatest risk for cardiovascular disease events between years 2 and 11 after diagnosis and higher in Black people or those with a discoid rash.
NEJM: 70 yoWM w/ 3-wk temporal headaches, jaw pain with chewing, temporal artery tender and thickened, but NO vision Sxs

Dr. John Cush RheumNow

3 years 11 months ago
NEJM: 70 yoWM w/ 3-wk temporal headaches, jaw pain with chewing, temporal artery tender and thickened, but NO vision Sxs. a 15, CRP 24 mg/L. and Doppler US showed “halo sign” . Temp art Bx confirmed the Dx of GCA https://t.co/mIUA8pMh2l https://t.co/o50MkidinC
J Rheum review shows 4,444 rheums in 2015 & 3,547 in 2020 recv some sort of pharma payments (There are ~5000 US Rheu

Dr. John Cush RheumNow

3 years 11 months ago
J Rheum review shows 4,444 rheums in 2015 & 3,547 in 2020 recv some sort of pharma payments (There are ~5000 US Rheums). Pandemic drops affected travel, etc (98%), speaking (72%), meals (72%), but less consulting (23%) https://t.co/2UMqp4XDhJ https://t.co/dHtHUBO1Wk
Downstream revenues from Rheum? The Rheumatologist reports and impt reference showing for every $1 dollar office visit b

Dr. John Cush RheumNow

3 years 11 months ago
Downstream revenues from Rheum? The Rheumatologist reports and impt reference showing for every $1 dollar office visit billed, $12.14 generated in downstream revenues (infusions, labs, surgery). Cognitive specialists are undervalued! https://t.co/YatkwrBCeQ https://t.co/OzSsxXKVhC
Review of risk factors for osteoporosis and fractures in #RA. OP Risk factors same as gen population (but more prevalent

Dr. John Cush RheumNow

3 years 11 months ago
Review of risk factors for osteoporosis and fractures in #RA. OP Risk factors same as gen population (but more prevalent in RA) - smoking, calcium intake, vit D deficiency, hypogonadism and chronic exposure to glucocorticoids https://t.co/KsE5ag29ZN https://t.co/OQtfoKcIX2
Co-administration of MTX with Folic Acid on the same day did not reduce efficacy compared to FA application one day afte

Dr. John Cush RheumNow

3 years 11 months ago
Co-administration of MTX with Folic Acid on the same day did not reduce efficacy compared to FA application one day after MTX. (based on AIA was induced in female Lewis rats) https://t.co/gBWhjhS8Nu https://t.co/5799lleK22
The results of a treat-to-target (T2T) combination therapy trial in patients with early rheumatoid arthritis (RA) show that if patients fail to respond initially, then a second, more intensified regimen can turn initial nonresponders into responders.
Urine proteomics on 54 SLE pts in the Belimumab–Lupus Nephritis trial, compared responders (n 31) v non-responders (n

Dr. John Cush RheumNow

3 years 11 months ago
Urine proteomics on 54 SLE pts in the Belimumab–Lupus Nephritis trial, compared responders (n 31) v non-responders (n 22), on BEL or SOC. Reduction in urinary CD163 was strongly associated with complete renal response @wk52 & CD23 @wk24 https://t.co/Rais8fKame https://t.co/F3B9W7u7VO
No Special Heart Risk With JAK Inhibitors, Study Finds

Patients taking JAK inhibitors for RA experienced similar cardi

Dr. John Cush RheumNow

3 years 11 months ago
No Special Heart Risk With JAK Inhibitors, Study Finds Patients taking JAK inhibitors for RA experienced similar cardiovascular outcomes as those using the TNF blocker adalimumab (Humira), analysis of French national registry data indicated. https://t.co/oUt1hz88ll https://t.co/RkUUvfC4YK
Sjogrens - Dx tips, myths & mistakes:
• SS not rare; affects 1 in 400
• 95% female, but SS is more severe in m

Dr. John Cush RheumNow

3 years 11 months ago
Sjogrens - Dx tips, myths & mistakes: • SS not rare; affects 1 in 400 • 95% female, but SS is more severe in men • African Americans have a severe systemic phenotype • Asians report dryness Sxs • Smoking & alcohol intake often avoided by SS pts https://t.co/B2hR7z8H5Z https://t.co/g0FKhcmoXa
×